FMR LLC - KERYX BIOPHARMACEUTICALS INC ownership

KERYX BIOPHARMACEUTICALS INC's ticker is KERX and the CUSIP is 492515101. A total of 126 filers reported holding KERYX BIOPHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 0.61 and the average weighting 0.1%.

Quarter-by-quarter ownership
FMR LLC ownership history of KERYX BIOPHARMACEUTICALS INC
ValueSharesWeighting
Q3 2018$1,954,000
-64.4%
574,734
-57.2%
0.00%
-100.0%
Q1 2018$5,493,000
-30.2%
1,343,145
-20.6%
0.00%0.0%
Q4 2017$7,867,000
-50.6%
1,691,764
-24.6%
0.00%
-50.0%
Q3 2017$15,923,000
-4.9%
2,242,664
-3.1%
0.00%0.0%
Q2 2017$16,735,000
+17.4%
2,314,6640.0%0.00%0.0%
Q1 2017$14,258,000
-1.5%
2,314,664
-6.3%
0.00%0.0%
Q4 2016$14,475,000
-14.0%
2,470,164
-22.0%
0.00%0.0%
Q3 2016$16,826,000
-19.8%
3,168,6640.0%0.00%
-33.3%
Q2 2016$20,977,000
+105.7%
3,168,664
+45.1%
0.00%
+200.0%
Q1 2016$10,200,000
-54.4%
2,184,192
-50.7%
0.00%
-66.7%
Q4 2015$22,354,000
+41.7%
4,426,492
-1.2%
0.00%
+50.0%
Q3 2015$15,775,000
-69.1%
4,481,497
-12.5%
0.00%
-71.4%
Q2 2015$51,101,000
-25.5%
5,120,392
-4.9%
0.01%
-22.2%
Q1 2015$68,570,000
+21.1%
5,386,492
+34.6%
0.01%
+28.6%
Q4 2014$56,612,000
+2.6%
4,000,792
-0.3%
0.01%0.0%
Q3 2014$55,151,000
-5.5%
4,010,992
+5.7%
0.01%
-12.5%
Q2 2014$58,378,000
-6.1%
3,795,700
+4.0%
0.01%
-11.1%
Q1 2014$62,199,000
+82.9%
3,650,200
+39.0%
0.01%
+80.0%
Q4 2013$34,008,000
+872.8%
2,626,100
+461.1%
0.01%
+400.0%
Q2 2013$3,496,000468,0000.00%
Other shareholders
KERYX BIOPHARMACEUTICALS INC shareholders Q2 2017
NameSharesValueWeighting ↓
Old West Investment Management, LLC 1,068,719$3,633,0001.50%
Abrams Capital Management 9,108,867$30,970,0000.82%
Baupost Group 25,791,678$87,692,0000.67%
Bristol Advisors, LLC 51,100$174,0000.29%
RICE HALL JAMES & ASSOCIATES, LLC 2,228,059$7,575,0000.27%
NEXTHERA CAPITAL LP 200,000$680,0000.13%
LINCOLN CAPITAL CORP 37,280$127,0000.10%
Meridian Wealth Management, LLC 49,600$169,0000.07%
Rubric Capital Management LP 199,883$680,0000.07%
Virtus ETF Advisers LLC 155,009$527,0000.05%
View complete list of KERYX BIOPHARMACEUTICALS INC shareholders